Nasdaq:US$8.83 (+0.24) | HKEX:HK$14.70 (-0.16) | AIM:£1.44 (-0.02)
新闻中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科学出版物 | 2014-06-03

ASCO 2014: A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer